arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Aspira Women's Health Inc.

AWHL
— Price unavailable
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
17 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

Aspira Women's Health Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap —
Dividend Yield —
Revenue Growth 0.4% ↗
Op. Margin -85.9% ↗
ROIC 110.5% ↘
FCF / Share $-0.21 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.26
info Valuation on last close.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.22M
— +0.4% —
Net Income Profit after all expenses
$-12.78M
↑ +2.4% —
Operating Margin Operating profit as % of sales
-85.9%
↑ +51.6% 3th
FCF / Share Free cash flow per share
$-0.21
↑ +76.0% —
Long-Term Debt Long-term obligations
$1.28M
↓ -15.3% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns
100
Financial Health ↑
55
Cash Quality ↓
42

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters